Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease

A Hye, F Kerr, N Archer, C Foy, M Poppe, R Brown, G Hamilton, J Powell, B Anderton, S Lovestone

Research output: Contribution to journalArticlepeer-review

109 Citations (Scopus)


Alzheimer's disease (AD) is a disorder without a molecular marker in peripheral tissues or a disease modifying treatment. As increasing evidence has suggested a role for glycogen synthase kinase-3 (GSK-3) in the pathogenesis of the condition we measured total GSK-3 protein (alpha and beta isoforms) and GSK-3 activity (serine 9 phosphorylation) in a group of healthy elderly people, in AD and in mild cognitive impairment (MCI). Total GSK-3 protein was increased in both AD and in MCI without a compensatory decrease in activity. These data suggest that GSK-3 assays might be a useful diagnostic marker in a readily available tissue and moreover that GSK-3 activity is increased in the prodromal phase of the disorder suggesting that inhibition of GSK-3 might be a useful therapeutic strategy. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)1 - 4
Number of pages4
JournalNeuroscience Letters
Issue number1
Publication statusPublished - 3 Jan 2005


Dive into the research topics of 'Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this